ChemicalBook--->CAS DataBase List--->99659-62-8

99659-62-8

99659-62-8 Structure

99659-62-8 Structure
IdentificationBack Directory
[Name]

ONO 6240
[CAS]

99659-62-8
[Synonyms]

ONO 6240
3-[(10-Ethoxy-8,12-dioxaoctacosan)-1-yl]thiazol-3-ium
3-[7-(2-ethoxy-3-hexadecoxypropoxy)heptyl]-1,3-thiazol-3-ium
[Molecular Formula]

C32H63NO6S2
[MOL File]

99659-62-8.mol
Hazard InformationBack Directory
[Description]

Ono 6240 is a platelet-activating factor antagonist. Studies suggest that Ono 6240 prevented airway eosinophilia by inhibiting production of IL-5 and IL-2 (Interleukin Levels). Results suggested that ONO-6240 may be of value in treating human asthmatic patients.
[Uses]

ONO-6240 is a platelet-activating factor antagonist. ONO-6240 prevents EOS infiltration into airway. ONO-6240 can be used in the study of asthmatic[1].
[References]

[1] Shi H, et al. [Effects of a platelet-activating factor antagonist ONO-6240 on antigen induced eosinophil infiltration into the airways]. Zhonghua Nei Ke Za Zhi. 1995 Nov;34(11):753-6. Chinese. PMID:8731847
99659-62-8 suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354 , +17819995354
Website: https://www.targetmol.com/
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354 , +17819995354
Website:
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Website: https://www.targetmol.cn/
Tags:99659-62-8 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.